Vertex Pharmaceuticals to Acquire Crinetics (CRNX) in $10 Billion Cash Deal

Vertex Pharmaceuticals to acquire Crinetics (CRNX) for $10 billion in all-cash deal at $85 per share, gaining key endocrinology drugs and pipeline assets.

The post Vertex Pharmaceuticals to Acquire Crinetics (CRNX) in $10 Billion Cash Deal appeared first on Blockonomi.